The first blood test for the early detection and prognosis of acute myeloid leukaemia
Acute myeloid leukaemia (AML) accounts for about 25% of all leukaemia in the Western world. Its overall survival rate for 5 years is the lowest of all types of leukaemia (27%): above 60% of AML patients will succumb to the disease.  Currently, there is no method for early detection of AML. It is diagnosed based on the presence of blasts in bone marrow samples and must be treated immediately to avoid a near-future death. Due to this late detection, AML treatment is of low effectiveness. 

The aggressive and often fatal nature of AML makes it a priority for developing early and fast diagnostic and prognostic tools.  We have identified a new biomarker for the early detection and prognosis of AML. This biomarker is detected and quantified by our innovative In vitro Diagnostic Test (IVD), named Serostrat, via a fast, cheap and routinely clinical blood analysis. We own the exclusive exploitation rights of SeroStrat. SeroStrat specifically targets the AML biomarker in blood cells, discriminates between AML unfavourable risk patients and AML patients with intermediate risks; is low-invasive and painfulness (only requires a blood sample instead of bone marrow samples); is fast and non-expensive (it can be used routinely in clinics in blood samples analysis by Flow cytometry) and will permit risk groups (persons aged >65), AML new patients, and persons in remission to be monitored easily and accurately for signs of recurrence.  

We are Leukos Biotech S.L. (Leukos), a Spanish spin-off company founded in 2015 from the prestigious Josep Carreras Leukaemia Research Institute.  Our goal is to enter fully into the biopharma sector, which will allow us to move to a business model which will create 50 new jobs and cumulative profits about € 22M by 2024.